Subject Accession	Species	Race	Race Specify	Ethnicity	Strain	Gender	Age Event	Age Event Specify	Subject Age	Age Unit	Subject Phenotype	ARM Accession	ARM Name	Study Accession	Study Brief Title	Biosample Accession	Biosample Description	Biosample Name	Biosample Type	Biosample Subtype	Study Time Collected	Study Time Collected Unit	Study Time T0 Event	Study Time T0 Event Specify	Biosample Treatment	Planned Visit Accession	Planned Visit Name	Experiment Accession	Expsample Accession	Expsample Description	Expsample Result Schema	Expsample Treatement	Reagent Accession	Reagent Name	Reagent Reporter Name	File Info ID	File Detail	File Name	Original File Name
SUB207025	Homo sapiens	Unknown	Benin native	Other		Female	Age at enrollment		25	Years		ARM5294	healthy	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101972			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401844		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788086	CyTOF result	HLA067_NK_normalized_healthy.788086.fcs	HLA067_NK_normalized_healthy.fcs
SUB207024	Homo sapiens	Unknown	Benin native	Other		Female	Age at enrollment		28	Years		ARM5294	healthy	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101971			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401843		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788085	CyTOF result	HLA060_NK_normalized_healthy.788085.fcs	HLA060_NK_normalized_healthy.fcs
SUB207022	Homo sapiens	Unknown	Benin native	Other		Female	Age at enrollment		46	Years		ARM5294	healthy	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101969			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401841		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788083	CyTOF result	HLA038_NK_normalized_healthy.788083.fcs	HLA038_NK_normalized_healthy.fcs
SUB209738	Homo sapiens	Unknown		Other		Female	Age at enrollment		41	Years	HIV-exposed seronegative sex worker	ARM5293	HESN	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101951			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401823		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788065	CyTOF result	D709T_NK_normalized_HESN.788065.fcs	D709T_NK_normalized_HESN.fcs
SUB209734	Homo sapiens	Unknown		Other		Female	Age at enrollment		34	Years	HIV-exposed seronegative sex worker	ARM5293	HESN	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101947			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401819		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788061	CyTOF result	D648T_NK_normalized_HESN.788061.fcs	D648T_NK_normalized_HESN.fcs
SUB209733	Homo sapiens	Unknown		Other		Female	Age at enrollment		53	Years	HIV-exposed seronegative sex worker	ARM5293	HESN	SDY1647	CD16 is upregulated in HIV-exposed seronegative women and may mediate enhanced antibody-dependent cytotoxicity	BS1101946			PBMC		0	Days	Time of enrollment			PV8900	Blood draw	EXP31070	ES1401818		FCM	no treatment	ESR25542, ESR25543, ESR25544, ESR25545, ESR25546, ESR25547, ESR25548, ESR25549, ESR25550, ESR25551, ESR25552, ESR25553, ESR25554, ESR25555, ESR25556, ESR25557, ESR25558, ESR25559, ESR25560, ESR25561, ESR25562, ESR25563, ESR25564, ESR25565, ESR25566, ESR25567, ESR25568, ESR25569, ESR25570, ESR25571, ESR25572, ESR25573, ESR25574, ESR25575, ESR25576, ESR25577, ESR25578, ESR25579, ESR25580, ESR25581, ESR25582, ESR25583, ESR25584, ESR25585, ESR25586	2B4.158Gd, CD14.143Nd, CD16.209Bi, CD19.146Nd, CD2.144Nd, CD3.115In, CD33.143Nd, CD38.141Pr, CD4.149Sm, CD45.102Pd, 104Pd, 106Pd, 108Pd, CD56.174Yb, CD57.89Y, CD62L.151Eu, CD69.142Nd, CD8.147Sm, CD94.167Er, CD96.165Ho, Cisplatin.194Pt/195Pt, CXCR6.168Er, DNA-1/DNA-2.191Ir/193Ir, DNAM-1.159Tb, FAS-L.160Gd, FcRg.148Nd, HLA-DR.Qdot? 655 (112Cd-114Cd), ki-67.152Sm, KIR2DL1/KIR2DS5.166Er, KIR2DL3.175Lu, KIR2DL5.170Er, NK.HESN.KIR2DS2.154Sm, KIR2DS4.153Eu, KIR3DL1.173Yb, LILRB1.145Nd, NKG2A.171Yb, NKG2C.163Dy, NKG2D.156Gd, NKp30.161Dy, NKp44.164Dy, NKp46.155Gd, NTB-A.172Tb, PD1.169Tm, Perforin.176Yb, Siglec-7.162Dy, Syk.150Nd, TIGIT.157Gd, CyTOF Panel 1	158Gd, 143Nd, 209Bi, 146Nd, 144Nd, 115In, 143Nd, 141Pr, 149Sm, 102Pd, 104Pd, 106Pd, 108Pd, 174Yb, 89Y, 151Eu, 142Nd, 147Sm, 167Er, 165Ho, 194Pt/195Pt, 168Er, 191Ir/193Ir, 159Tb, 160Gd, 148Nd, Qdot? 655 (112Cd-114Cd), 152Sm, 166Er, 175Lu, 170Er, 154Sm, 153Eu, 173Yb, 145Nd, 171Yb, 163Dy, 156Gd, 161Dy, 164Dy, 155Gd, 172Tb, 169Tm, 176Yb, 162Dy, 150Nd, 157Gd, 	788060	CyTOF result	D647T_NK_normalized_HESN.788060.fcs	D647T_NK_normalized_HESN.fcs
